Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.

Inflamm Bowel Dis · 2024 · PMC10769800 · PMID 36946138

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

close to significanceP = .05actually significant

However, significant differences ( P < .05) or differences close to significance ( P = .05) were observed between the placebo population of the SELECTION trial and those of the GEMINI 1, OCTAVE SUSTAIN, and UNIFI trials for all assessed outcomes.

also in 459 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.